Sharda Cropchem Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/xi3io17lux951mxvhci10uj1.pdf

Key Takeaways


Demand & Volume Recovery

Bubna: "I feel it is demand on the ground."

Margins: The Expansion & The Unexplained Gap

Bubna: "We feel it is sustainable."

Pricing & Foreign Exchange


Non-Agrochemical Business: Unanswered Questions


Capital Allocation & Tariffs

Bubna: "We want to run our business very comfortably and peacefully. So we are ready for any adverse situations and still be able to maintain our business."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth15% growth for FY26FY26
Gross marginSustain at 35%–36%FY26 full year
EBITDA margin15%–18% range, trending toward the higher side of 15% or above 18%FY26
CAPEX₹400–₹450 cr backed by strong pipelineFY26
Revenue growth pace25% sales growth can sustain over coming quartersComing quarters
Forex levelsRemain at same levelFY26
Product registrationsAim to increaseOngoing
Dividend postureMore liberal in payouts, dividends, rewarding shareholdersNo timeline given

Key Metrics

MetricQ1 FY26
Revenue₹985 cr, +25% YoY
Agrochemical revenue₹846 cr, +25% YoY
Non-agrochemical revenue₹139 cr, +31% YoY
Overall volume growth13.2% YoY
Gross margin35.5%, +630 bps YoY from 29.2%
EBITDA₹142 cr, +67% YoY
EBITDA margin14.4%
PAT₹143 cr, +424% YoY from ₹27 cr
Revenue growth compositionVolume ~13%, forex ~13%, price and product mix negative 1%
Gross margin, Europe43%
Gross margin, NAFTA26%
Gross margin, LATAM28%
Gross margin, rest of world26.5%
Working capital days100 days, improved 18 days vs March 2025
CAPEX₹114 cr for the quarter
Cash, bank and liquid investments₹791 cr as on 30 June 2025
Total product registrations2,981 as on 30 June 2025, with 1,021 applications at approval stage
FY26 revenue growth guidance15%
FY26 EBITDA margin guidance15%–18%
FY26 planned CAPEX₹400–₹450 cr
Top 10 molecules revenue share36% of total revenue, vs 38% in Q1 last year